Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.
Herpes simplex virus (HSV1) infections are initiated at mucosal surfaces where the virus infects epithelial cells.
A recent Israeli study points toward Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) as a potentially effective tool for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on-the-spot detection by using swabs or saliva – addressing the community need for simple surveillance.
In November of 2019--likely, even earlier--a tiny entity measuring just a few hundred billionths of a meter in diameter began to tear apart human society on a global scale.
Until now, scientists had assumed that there are about 80 so-called open reading frames (ORFs) in the genome of herpes simplex virus 1 (HSV-1).
From the plagues of medieval Europe to the influenza pandemic of 1918, the specter of the next public health disaster has gripped the minds of scientists, captivated the imaginations of writers and vexed conspiracy theorists.
Physician-scientists at four University of California Health medical centers -- UC San Diego Health, UC San Francisco, UC Irvine Health and UC Davis Health -- have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, an antiviral drug that has shown activity in animal models and human clinical trials of SARS-CoV, MERS-CoV, Ebola, Marburg and other viruses.
CEL-SCI Corporation announced today it has signed a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy.
Without even knowing it, most of us carry around latent Herpes Simplex Virus in our nervous system- a simple result of being born and living together with others carrying the virus.
A new study released today in the Journal of Virology gives insights into how the HIV-1 virus, which often persists in the body despite antiretroviral treatment, reemerges when treatment stops. More importantly, the study also gives clues on how to stop this reemergence from occurring.
An Italian research team has refined the history and origins of two extremely common pathogens in human populations, herpes simplex virus type 1 and type 2.
Johns Hopkins researchers report that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a "suicide gene" to pediatric brain tumor cells implanted in the brains of mice.
The herpes simplex virus, commonly known as the cold sore virus, is a devious microbe.
Researchers at the University of Arizona College of Medicine - Phoenix have discovered a function in a pro-inflammatory protein that could play an important part in improving current and future therapeutics for the herpes virus.
Professors Xiangmin Xu and Rozanne Sandri-Goldin, in collaboration with Professors Bert Semler and Todd Holmes at the University of California, Irvine, School of Medicine, were awarded a three-year, $4.3 million Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative grant.
Genital herpes, caused by the herpes simplex virus 2 (HSV-2) is a very common sexually transmitted infection (STI). It affects 14% of Americans aged 15-49 years. There is no herpes vaccine at present. Many failed attempts at vaccine production have centered around HSV proteins.
Scientists from the Skoltech Center for Energy Science and Technology and the Institute of Problems of Chemical Physics of RAS in collaboration with researchers from four other Russian and foreign research centers have discovered a new reaction that helps obtain water-soluble fullerene derivatives which effectively combat flu viruses, human immunodeficiency virus, herpes simplex virus, and cytomegalovirus.
Researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a vaccine to protect against genital herpes.
A novel charcoal-based drug-delivery system to treat herpes infections topically shows greatly improved efficacy over conventional treatment. Here, the medication called acyclovir, commonly used for herpes infection, was combined with activated carbon particles.
Yale investigators have shown that the combination of a vaccine and a medicated cream is a promising strategy to dramatically reduce the recurrence of genital herpes.